Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +7.08% | +3.63% | +45.20% |
05-14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
05-14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.20% | 481M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.56% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Canaccord Genuity Adjusts Price Target on Taysha Gene Therapies to $6 From $7, Maintains Buy Rating